A Phase 1, Multicenter, Open-label, Dose Exploration and Dose Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 994 Monotherapy and Combination of AMG 994 and AMG 404 in Subjects With Advanced Solid Tumors
Latest Information Update: 25 Sep 2023
At a glance
- Drugs AMG 994 (Primary) ; Zeluvalimab (Primary)
- Indications Adenocarcinoma; Brain metastases; Carcinoma; Mesothelioma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours; Squamous cell cancer
- Focus Adverse reactions
- Sponsors Amgen
- 20 Sep 2023 Status changed from active, no longer recruiting to completed.
- 14 Jun 2023 Planned End Date changed from 7 Aug 2024 to 19 Sep 2023.
- 16 Nov 2022 Planned End Date changed from 7 Mar 2023 to 7 Aug 2024.